Pankomab, an antibody targeting this carbohydrate-induced conformational tumor-associated epitope on MUC1, features the highest glycosylation dependency and strongest additive binding effect compared to past MUC1 antibodies (Danielczyk et al., 2006). This evidence concerns the gene MUC1 and neoplasm.